What is: XOMA (Xoma Corporation)

What is XOMA (Xoma Corporation)

XOMA Corporation is a biotechnology company that focuses on the discovery and development of antibody-based therapeutics. The company’s primary goal is to create innovative treatments for a variety of diseases, including cancer, inflammatory conditions, and infectious diseases.

One of the key strengths of XOMA is its expertise in antibody technology. The company has developed a proprietary platform that allows for the rapid identification and optimization of antibodies with therapeutic potential. This technology has enabled XOMA to create a diverse pipeline of drug candidates that target a range of disease pathways.

XOMA’s lead product candidate is gevokizumab, a monoclonal antibody that is being developed for the treatment of inflammatory conditions such as pyoderma gangrenosum and Behçet’s disease. The company is also exploring the potential of gevokizumab in other indications, including cardiovascular disease and cancer.

In addition to gevokizumab, XOMA has a number of other antibody-based therapeutics in development. These include XOMA 358, a potential treatment for hyperinsulinemic hypoglycemia, and XOMA 213, a candidate for the treatment of acute severe hypoglycemia.

Overall, XOMA Corporation is a biotechnology company that is focused on developing innovative antibody-based therapeutics for a range of diseases. With a strong pipeline of drug candidates and a proprietary technology platform, XOMA is well-positioned to make significant contributions to the field of biotechnology in the coming years.